You are here: Welcome to the MPKB » Welcome to the MPKB » Special issues » Children and the Marshall Protocol
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
home:special:children [10.26.2018] – [Patient interviews] sallieqhome:special:children [09.14.2022] (current) – external edit 127.0.0.1
Line 2: Line 2:
 ====== Children and the Marshall Protocol ====== ====== Children and the Marshall Protocol ======
  
-Children with a range of [[home:diseases|diseases and conditions]] can be treated with the Marshall Protocol (MP). There are more than a dozen in the study cohort who are doing well, and others who are being treated by family physicians, not regularly reporting. Benicar is [[http://www.prnewswire.com/news-releases/fda-approves-benicarr-for-the-treatment-of-high-blood-pressure-in-children-and-adolescents-aged-6-16-84104997.html|approved by the FDA]] for use in children and adolescents 6 to 16 years of age. +Children with a range of [[home:diseases|diseases and conditions]] can be treated with the Marshall Protocol (MP). There are more than a dozen in the study cohort who are doing well, and others who are being treated by family physicians, not regularly reporting. Benicar is [[https://www.prnewswire.com/news-releases/fda-approves-benicarr-for-the-treatment-of-high-blood-pressure-in-children-and-adolescents-aged-6-16-84104997.html|approved by the FDA]] for use in children and adolescents 6 to 16 years of age. 
  
  
Line 12: Line 12:
 ===== Safety ===== ===== Safety =====
  
-When considering any treatment plan, the physician (and the patient) should weigh the risks versus the benefits. When compared to other protocols or medications that sick children are customarily given for Th1 inflammatory disease, the decision to go with the MP is usually self-evident. Physicians can find support for managing a child by posting in the [[http://www.marshallprotocol.com/forum17/|MP Health Professionals Forum]]. Physicians may also directly contact Prof. Marshall by phone.+When considering any treatment plan, the physician (and the patient) should weigh the risks versus the benefits. When compared to other protocols or medications that sick children are customarily given for Th1 inflammatory disease, the decision to go with the MP is usually self-evident. Physicians can find support for managing a child by posting in the [[https://www.marshallprotocol.com/forum17/|MP Health Professionals Forum]]. Physicians may also directly contact Prof. Marshall by phone.
  
  
Line 30: Line 30:
 The olmesartan (Benicar) dosage for a child should be considered on an individual basis, case by case. **A simple weight ratio is often not helpful**, as the distribution volume for the drug varies greatly with disease severity, even for people of a similar weight. A physician needs to consider symptoms, lab work and the level of 1,25-D when deciding on the optimal dosing for a child. More seriously ill children often need the same dose of Benicar as do some of the adults. The olmesartan (Benicar) dosage for a child should be considered on an individual basis, case by case. **A simple weight ratio is often not helpful**, as the distribution volume for the drug varies greatly with disease severity, even for people of a similar weight. A physician needs to consider symptoms, lab work and the level of 1,25-D when deciding on the optimal dosing for a child. More seriously ill children often need the same dose of Benicar as do some of the adults.
  
-Daiichi Sankyo, Inc. [[http://www.prnewswire.com/news-releases/fda-approves-benicarr-for-the-treatment-of-high-blood-pressure-in-children-and-adolescents-aged-6-16-84104997.html|announced in 2010]] that the U.S. Food and Drug Administration (FDA) has approved the Benicar for use in children and adolescents 6 to 16 years of age.  Benicar was originally approved in 2002 for the treatment of hypertension in adults. The FDA has set no dose at which Olmesartan is considered unsafe, in children or in adults.+Daiichi Sankyo, Inc. [[https://www.prnewswire.com/news-releases/fda-approves-benicarr-for-the-treatment-of-high-blood-pressure-in-children-and-adolescents-aged-6-16-84104997.html|announced in 2010]] that the U.S. Food and Drug Administration (FDA) has approved the Benicar for use in children and adolescents 6 to 16 years of age.  Benicar was originally approved in 2002 for the treatment of hypertension in adults. The FDA has set no dose at which Olmesartan is considered unsafe, in children or in adults.
  
  
Line 87: Line 87:
 autism, ADHD, depression, severe anxiety, chronic fatigue syndrome (CFS) autism, ADHD, depression, severe anxiety, chronic fatigue syndrome (CFS)
  
-Read the [[http://bacteriality.com/2008/03/15/interview18/|interview]]+Read the [[https://bacteriality.com/2008/03/15/interview18/|interview]]
  
 <html></div></div></html> <html></div></div></html>
Line 94: Line 94:
 <div class="patientinterviewboxr"> <div class="patientinterviewboxr">
  
-{{tag> special Special_issues}}+{{tag>special children Special_issues}}
 <div class="patientinterviewimage"></html>{{:home:patients:robyn.gif?nolink|}}<html></div> <div class="patientinterviewimage"></html>{{:home:patients:robyn.gif?nolink|}}<html></div>
 <div class="patientinterviewtext"> <div class="patientinterviewtext">
Line 101: Line 101:
 Lyme, myoclonus Lyme, myoclonus
  
-Read the [[http://bacteriality.com/2007/10/28/interview6/|interview]]+Read the [[https://bacteriality.com/2007/10/28/interview6/|interview]]
  
 <html></div></div> <html></div></div>
Line 123: Line 123:
  
  
 +<nodisp>
 ===== Notes and comments ===== ===== Notes and comments =====
  
Line 132: Line 133:
 </blockquote> </blockquote>
  
-===== References =====+===== References =====</nodisp> 
home/special/children.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.